Dogwood Therapeutics Inc expected to post a loss of $2.37 a share - Earnings Preview

Dogwood Therapeutics

05/05/2025 13:47

Dogwood Therapeutics Inc DWTX.OQ DWTX.O is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Dogwood Therapeutics Inc is for a loss of $2.37 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Dogwood Therapeutics Inc is $11.00​, above​ its last closing price of $5.02. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-1.49
-1.41
-5.87
Missed
-314.8
Sep. 30 2024
-1.10
-1.18
-2.05
Missed
-74.2
Jun. 30 2024
-1.56
-1.58
-1.25
Beat
21​
Mar. 31 2024
-1.00
-1.00
-1.75
Missed
-75
​​Dec. 31 2023
-2.24
-2.25
-1.50
Beat
33.3
Sep. 30 2023
-2.37
-2.37
-1.50
Beat
36.8​
Jun. 30 2023
-1.75
-1.75
-2.00
Missed
-14.3
Mar. 31 2023
-5.00
-5.00
-2.00
Beat
60

This summary was machine generated May 5 at 12:47 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)